Overview

Rocklatan® Evaluation

Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate whether the IOP lowering with Rocklatan® is similar, or demonstrates additional IOP lowering, in subjects on a current regimen of latanoprost alone or latanoprost plus addition of either one or two individual agents/bottles with another mechanism of action.
Phase:
Phase 4
Details
Lead Sponsor:
Aerie Pharmaceuticals
Treatments:
Latanoprost
Ophthalmic Solutions